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Abstract
Introduction: Patients with hypogonadism are at increased risk of cardiac and metabolic diseases and osteoporosis. Vitamin D and fibroblast 
growth factor-23 (FGF-23) play a role in the regulation of bone mineral metabolism and endothelial functions. Low vitamin D levels are 
reported in hypogonadism, while there is no data about the effect of testosterone replacement therapy (TRT). We investigated the effect 
of TRT on vitamin D and FGF-23 levels along with endothelial functions and insulin resistance in hypogonadal patients. 
Material and methods: Patients with congenital hypogonadotrophic hypogonadism (CHH) (n = 32, age 20.6 ± 1.58 years) were enrolled. 
TRT was implemented in transdermal form. The demographic parameters, FGF-23, 25(OH)D3, asymmetric dimethylarginine (ADMA), 
and homeostatic model assessment of insulin resistance (HOMA-IR) levels, were measured both before and after TRT. 
Results: After a follow-up period of 3.63 ± 1.33 months, ADMA and FGF-23 levels were significantly increased (p = 0.03 and p = 
0.005 respectively), while 25(OH)D3 and HOMA-IR index were not significantly changed. The body mass index and waist circum-
ference levels of the patients were also increased (p < 0.001 and p = 0.02) along with a significant decrease in the HDL cholesterol 
levels (p = 0.006). 
Conclusions: The results show that short-term TRT increases plasma FGF-23 and ADMA levels but does not alter the vitamin D levels 
in young, treatment naive patients with CHH. Whether this is an early implication of TRT-related adverse effects in this very young and 
treatment naïve population of CHH is not clear. Future prospective studies are required to find out the long-term effects of TRT on cardio-
metabolic morbidity and mortality in this specific population. (Endokrynol Pol 2017; 68 (3): 311–316) 
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Streszczenie
Wstęp: U chorych z hipogonadyzmem występuje zwiększone ryzyko chorób sercowych I metabolicznych oraz osteoporozy. Witamina 
D i czynnik wzrostu fibroblastów-23 (FGF-23) uczestniczą w regulacji metabolizmu kostnego i czynności śródbłonka. Istnieją doniesienia 
na temat niskiego stężenia witaminy D w hipogonadyzmie, natomiast brakuje danych dotyczących wpływu testosteronowej terapii 
zastępczej (TRT) na to stężenie. Autorzy zbadali wpływ TRT na stężenia witaminy D i FGF-23 oraz na czynność śródbłonka i poziom 
insulinooporności u chorych z hipogonadyzmem. 
Materiał i metody: Do badania włączono chorych z wrodzonym hipogonadyzmem hipogonadotropowym (CHH) (n = 32, wiek 20,6 ± 
1,58 roku). Chorzy otrzymywali TRT w postaci przezskórnej. Przez rozpoczęciem leczenia i po jego zakończeniu u chorych zebrano dane 
demograficzne, zmierzono stężenia FGF-23, 25(OH)D3 i asymetryczej dimetyloargininy (ADMA) oraz określono wskaźnik insulinooporności 
HOMA-IR. 
Wyniki: Po okresie obserwacji trwającym 3,63 ± 1,33 miesiąca stwierdzono istotne zwiększenie stężeń ADMA i FGF-23 (odpowiednio 
p = 0,03 i p = 0,005), natomiast stężenie 25(OH)D3 i wskaźnik HOMA-IR nie zmieniły się istotnie. Ponadto zaobserwowano u chorych 
zwiększenie wskaźnika masy ciała i obwodu pasa (p < 0,001 I p = 0,02) oraz istotne zmniejszenie stężenia cholesterol frakcji HDL (p = 0,006).
Wnioski: Wyniki badania pokazują, że krótkotrwałe stosowanie TRT u młodych chorych z CHH, uprzednio nieleczonych, powoduje 
zwiększenie osoczowego stężenia FGF-23 i ADMA, lecz nie wpływa na stężenie witaminy D. Nie jest jasne, czy jest to wczesny efekt 
działań niepożądanych TRT w tej grupie bardzo młodych pacjentów z CHH. Konieczne są dalsze prospektywne badania w celu ustalenia 
długookresowego wpływu TRT na chorobowość i śmiertelność w związku z chorobami sercowymi i metabolicznymi w tej szczególnej 
populacji.  (Endokrynol Pol 2017; 68 (3): 311–316)
Słowa kluczowe: hipogonadyzm; witamina D; czynnik wzrostu fibroblastów-23; asymetryczna dimetyloarginina
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Introduction
The clinical features of hypogonadism are far beyond 
the lack of fertility. The risk of cardiac and metabolic 
disorders such as obesity, type 2 diabetes, and athero-
sclerotic cardiovascular diseases [1, 2] are significantly 
increased. Also, bone mineral metabolism disorders, 
such as osteoporosis, are prevalent in patients with 
hypogonadism [3–5]. Positive correlations between 
testosterone and vitamin D levels were reported in 
several cross-sectional studies in hypogonadal subjects 
[6-8]. However, very few studies have been performed 
so far to investigate the effect of testosterone replace-
ment therapy (TRT) on vitamin D levels [9].
Fibroblast growth factor-23 (FGF-23) is a novel osteo-
cyte-derived hormone, which regulates phosphate, vita-
min D, and bone mineral metabolism [10–12]. FGF-23 also 
plays role in the pathogenesis of endothelial dysfunction 
and atherosclerosis [13-15]. There is a competitive in-
teraction between the levels of FGF 23 and asymmetric 
dimethylarginine (ADMA), a well-documented surrogate 
for endothelial dysfunction [15]. Despite the significant 
impairment of endothelial functions and bone mineral 
metabolism in hypogonadism, little is known about the 
levels of FGF-23 and the role it plays in these patients 
[16, 17]. Also, there are no data about the effect of TRT 
on FGF-23 levels in patients with hypogonadism. 
We designed the following study to search for any 
effect of TRT on the vitamin D and FGF-23 levels in 
patients with hypogonadism. Also, we searched for any 
relationship between FGF-23 and Vitamin D levels or 
the surrogate markers of endothelial dysfunction and 
insulin resistance.
Material and methods
Military service is compulsory for every young man in 
Turkey. Gulhane Military Medical Academy School of 
Medicine is the tertiary medical centre for all the mili-
tary recruits. Patients with hypogonadism are referred 
to the Department of Endocrinology and Metabolism 
for treatment and follow-up. Some of these hypogo-
nadal patients, generally the ones living in the rural 
regions, have never been treated before. Information 
about the enrolment criteria and the testosterone re-
placement procedures of our hypogonadal cohort were 
given in detail in previous articles [18–20]. Briefly, young 
patients diagnosed as CHH, who were not treated with 
testosterone replacement and who did not have any 
other chronic diseases, were enrolled. 
Thirty-two treatment-naive patients (age 20.6 ± 
1.58 years) with CHH were enrolled in the study. The 
diagnosis of CHH was based on a failure to undergo 
spontaneous puberty, specific physical findings of hy-
pogonadism, such as infantile genitalia (Tanner stages 
1 or 2), eunuchoid proportions, high-pitched voice, and 
sparse male-pattern body hair; and laboratory results 
showing hypogonadotrophic hypogonadism (low 
testosterone, normal or low gonadotrophins, and nor-
mal pituitary functions). None of the patients had any 
chronic disorders or were previously given testosterone 
or human chorionic gonadotropin (hCG) therapy. All 
patients gave informed consent, and the Local Ethical 
Committee of Gulhane School of Medicine approved 
the study. This study has been registered to Clinicaltri-
als.gov (NCT02111473).
The height, weight, and waist circumference (WC) 
of the patients were measured with their underwear. 
Body mass index (BMI) was computed as the ratio of 
weight to the square of height (kg/m²). WC was meas-
ured, after the patients exhaled, from the line on the 
iliac crest, which is parallel to the ground. Pubertal de-
velopments of the patients were assessed according to 
the Tanner stages. Pituitary hormones were evaluated 
in all patients to exclude panhypopituitarism. Pituitary 
or hypothalamic mass lesions were excluded by mag-
netic resonance imaging. The 25(OH)D3 and FGF-23 
levels of some patients presented here were involved 
in a previous case control study [17]. The present study 
is designed to evaluate the effect of TRT during the 
follow-up period.
Testosterone replacement therapy 
The patients enrolled in this study were treated with 
transdermal testosterone gel (Testogel 50 mg gel) ap-
plied every night. The blood samples for the evalua-
tion of the baseline metabolic parameters were taken 
before the first testosterone dosage. The patients were 
then reevaluated in the third and/or sixth months of 
treatment. 
Sample collection and laboratory measurements
For biochemical analyses, all blood samples were col-
lected from the antecubital vein, between 08:00 and 
09:00 after an overnight fasting. The samples were 
centrifuged for 15 minutes at 4000 rpm, aliquoted, and 
immediately frozen at –80°C for analyses. Fasting blood 
glucose (FBG), total cholesterol, triglyceride (TG), and 
high-density lipoprotein cholesterol (HDL-C) levels 
were measured by the enzymatic colorimetric method 
with an Olympus AU2700 auto analyser using reagents 
from Olympus Diagnostics (GmbH, Hamburg, Ger-
many). Low-density lipoprotein cholesterol (LDL-C) 
was calculated by Friedewald’s formula [21]. The 
serum basal insulin, testosterone, FSH, and LH were 
measured by the electrochemiluminescence method 
with the UnicelDXI 800 Access Immunoassay System 
(Miami, FL, ABD). Insulin sensitivity was calculated 
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by using the homeostatic model assessment of insulin 
resistance (HOMA-IR) index by the formula: HOMA-IR 
= (insulin × glucose)/405 [22]. Plasma asymmetric 
dimethylarginine (ADMA) levels were determined by 
ELISA (Immundiagnostik, Bensheim, Germany). The 
minimum detectable concentration for ADMA was 
0.05 µmol/L. Plasma FGF-23 levels were determined 
by ELISA, (Human Intact FGF-23 ELISA Kit, Inc., 
San Clemente, CA, USA). The minimum detectable 
concentration for FGF-23 was 1.0 pg/mL. Intra-assay 
coefficient of variation (CV) ranged from 2.6% to 4.4%, 
while inter-assay CV ranged from 6.1% to 6.5% for 
FGF-23. Measurements were carried out using ELISA 
plate reader Bio-Tek Synergy HT [Biotek Instruments 
Inc., Winooski, VT, USA]. Plasma 25(OH)D3 levels were 
measured by Immuchrom kits (Immuchrom, Hessen, 
Germany) using isocratic HPLC method with UV detec-
tor in the Shimadzu Prominence HPLC system. 
Statistical analysis
All data were recorded on a computer database and 
analysed using SPSS 18.0 package program (SPSS, 
Inc.,Chicago, IL, USA). Results are expressed as mean 
± S.D. The correlations were performed by using the 
Pearson’s or Spearman’s Correlations tests. The vari-
ables were assessed for normality using Kolmogorov- 
-Smirnov test. Intra-group changes at two time points 
were analysed by paired samples t-test. Differences 
were considered significant at p < 0.05. 
Results
The clinical and laboratory characteristics of the pa-
tients, both before and after the TRT, are given in Table I. 
The follow-up period of the patients under TRT is 3.63 
± 1.33 months. According to the results, the secondary 
sexual characteristics of the patients were significantly 
improved from Tanner stages 1–2 to stages 3–4. Also, 
the BMI, WC measures (p < 0.001 and p = 0.02), and 
FBG levels (p = 0.007) were significantly increased 
and HDL-C levels were significantly decreased 
(p = 0.006) during the follow-up period. On the other 
hand, serum FGF-23 and ADMA levels significantly 
increased (p = 0.005 and p = 0.03, respectively), while 
the 25(OH)D3 and HOMA-IR index were not signifi-
cantly changed (Fig. 1). No significant correlation was 
found between the serum levels of total testosterone, 
FGF-23, 25(OH)D3, ADMA, or the HOMA-IR indexes. 
No significant side effects were reported during the 
study period.
Table I. Clinical and laboratory characteristics of patients before and after testosterone replacement therapy
Tabela I. Parametry kliniczne i laboratoryjne u chorych przed leczeniem i po zastosowaniu testosteronowej terapii zastępczej
Before treatment 
(n = 32)
After treatment 
(n = 32)
p*
Age (years) 20.6 ± 1.58
SBP [mmHg] 123.1 ± 17.3 123.1 ± 13.0 0.98
DBP [mmHg] 73.5 ± 8.2 69.2 ± 9.9 0.11
BMI [kg/m²] 21.8 ± 2.7 23.4 ± 3.1 < 0.001
WC [cm] 80.8 ± 10.4 84.6 ± 10.6 0.02
FSH [mIU/mL] ** 0.64 (0.33-0.96) 0.43 (0.29-0.93) 0.79
LH [mIU/mL] ** 0.29 (0.20-0.94) 0.38 (0.20-0.89) 0.31
Total Testosterone [ng/dl] 32.6 ± 22.1 194.8 ± 205.8 < 0.001
HDL-C [mg/dl] 48.1 ± 9.6 43.1 ± 9.0 0.006
TG [mg/dl]** 120.0 (70.0-225.0) 108 (90.0-174.0) 0.63
FBG [mg/dl] 88.8 ± 6.4 93.0 ± 5.7 0.007
INSULIN** 11.5 (6.3-16.5) 10.4 (8.2-15.5) 0.50
HOMA-IR** 2.36 (1.43-3.26) 2.34 (1.77-3.60) 0.12
FGF-23 [pg/mL] 66.3 ± 26.7 88.8 ± 37.6 0.005
ADMA [µmol/L] 0.75 ± 0.15 0.87 ± 0.21 0.03
25[OH]D3 [nmol/L] 17.3 ± 8.2 20.0 ± 8.3 0.23
* Paired samples t test. 
** Mann-Whitney U test. Results are given as mean (25–75%) 
SBP — Systolic blood pressure, DBP — Diastolic blood pressure, BMI — Body mass index, WC — Waist circumference, FSH — Follicle stimulating hormone,  
LH — Luteinising hormone, HDL-C — High-density lipoprotein cholesterol, TG — Triglyceride, FBG — Fasting blood glucose, HOMA-IR — Homeostatic model 
assessment-insulin resistance, FGF-23 — Fibroblast growth factor-23, ADMA — Asymmetric dimethylarginine
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Discussion
The results of the present study show that TRT for 
about four months has no significant effect on Vitamin 
D levels but increases plasma FGF-23 and ADMA levels 
in treatment naïve, young patients with congenital 
hypogonadism. The BMI and WC of these patients 
also increase along with a decrease in HDL-C levels. 
Whether these findings are the early implications of 
TRT-related adverse cardio-metabolic outcomes will 
be discussed below. 
Osteoporosis and increased fracture risk is a sig-
nificant feature of hypogonadism [23–26]. The exact 
mechanism of impaired skeletal health in hypogonadal 
subjects is not clearly explained [27]. Recent data has 
shown that vitamin D levels are lower and significantly 
correlated with low testosterone levels in hypogonadal 
males [6–8]. The expression of vitamin D receptor and 
vitamin D metabolising enzymes in the human testis 
[28] or the impairment of the renal 1α-hydroxylase 
activity due to low testosterone levels [29] show 
a close functional relationship between testosterone 
and vitamin D. Another key regulator of vitamin D 
and phosphate metabolism is FGF-23, a bone-derived 
hormone improving renal phosphate excretion and pre-
venting the activation of vitamin D levels [11, 12]. The 
role of FGF-23 in hypogonadal patients has not been 
clearly defined. In an interventional study of healthy 
male volunteers who were experimentally exposed to 
gonadotropin releasing hormone (GnRH) analogue, 
no alteration was observed in FGF-23 levels [16]. 
Recently, we have reported that FGF-23 levels in con-
genital hypogonadism are not significantly different 
from the healthy controls, while the vitamin D levels 
tend to be lower [17]. 
Both metabolic and cardiovascular diseases are 
prevalent in patients with hypogonadism [30–33]. 
Several studies show that TRT improves cardiovascular 
risk factors such as fasting glucose levels, insulin sensi-
tivity, arterial blood pressure, or total cholesterol levels 
[34–36]. However, the metabolic benefits of TRT may 
have been exaggerated at least in some of the previous 
studies [37]. Contrary to the data on the metabolic and 
cardiovascular benefits, increased cardiovascular events 
were reported in hypogonadal patients under TRT 
[38–41]. Most of these studies showing adverse effects 
of TRT were by and large performed on frail elderly 
populations with several confounders. However, we 
also reported endothelial dysfunction, inflammation 
and insulin resistance after TRT in unconfounded, 
young hypogonadal patients [18-20]. To our knowledge, 
the present study is the first to search for the effect of 
TRT on 25(OH)D3 and FGF-23 levels . FGF 23 is not 
only secreted from osteocytes but also from the vascular 
endothelium [42]. FGF-23 elevation plays a role in the 
pathogenesis of endothelial dysfunction [14, 43], athe-
rosclerosis [13], and left ventricular hypertrophy [44]. 
On the other hand, ADMA is an endogenous inhibitor 
of nitric oxide production and a promising biomarker 
for cardiovascular diseases [45]. To our knowledge, 
very few studies have reported the effect of TRT on 
ADMA levels in the literature. Two of these studies, 
which have significant limitations, report decreased 
ADMA levels after TRT. ADMA levels were measured 
only a few days after a single injection in one study 
[46], and only 10 middle aged or elderly patients with 
different aetiologies and several comorbidities were 
enrolled in the other [47]. However, plasma ADMA 
levels did not improve but worsened after TRT in our 
homogenous study population. This is in accordance 
with our previous report of a similar follow-up study 
in a CHH population [20]. The mechanism of this in-
crease in ADMA levels after TRT is not clear. There is 
a significant interaction between the elevated FGF-23 
Figure 1. Comparison of plasma ADMA (A) and FGF-23 (B) levels before and after testosterone replacement therapy
Rycina 1. Porównanie stężeń w osoczu ADMA (A) I FGF-23 (B) przed i po testosteronowej terapii zastępczej
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and ADMA levels in terms of the renal and cardiovas-
cular outcomes [15]. The increase in both markers after 
TRT may be an early indicator of adverse cardiovascular 
events in CHH. 
There are several limitations of this study. The 
relatively short follow-up period and the small study 
population preclude further mechanistic comments. In 
addition, the effect of the season and sun exposure on 
the measurement of 25(OH)D3 levels were ignored in 
the study. Most importantly, this specific population of 
treatment naïve young patients with CHH may not rep-
resent the elderly hypogonadal patients. In our CHH 
group, the secondary sexual characteristics significantly 
improved, but the BMI and WC were increased after 
the TRT. A general response that we observed in this 
study population is a significant improvement in the 
secondary sexual characteristics along with a significant 
increase in BMI and WC [17–20]. It is likely that TRT 
ignites pubertal growth in these young patients, which 
is not seen in elderly hypogonadal patients of other 
aetiologies This may partly explain the rapid increase in 
BMI and waist circumference of these patients. Despite 
these limitations, this study has significant advantages 
regarding the homogeneous study population and 
lack of confounding factors, such as chronic metabolic 
disorders and concomitant medications.
Conclusions
The results of the present study show that TRT in 
young, treatment naive patients with CHH does not 
have a significant effect on 25(OH)D3 levels, but it 
increases plasma FGF-23 and ADMA levels. However, 
whether these metabolic effects will result in adverse 
cardiovascular outcomes in the long term is not clear. 
Future prospective studies are required to find out 
the long-term effects of testosterone replacement on 
vitamin D levels and cardiovascular morbidity and 
mortality in this specific population. 
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